The global AI in drug discovery market size is estimated to grow from USD 1.81 billion in the current year to USD 41.08 billion by 2040, at a CAGR of 25% during the forecast period, till 2040. The new study provides market size, growth scenarios, industry trend and future forecast.
Artificial intelligence (AI) is revolutionizing drug discovery by speeding up the process, lowering costs, and enhancing success rates through methods, such as virtual screening, predictive modeling for efficacy and toxicity, and de novo drug design. Machine learning and deep learning techniques evaluate large datasets to pinpoint promising drug candidates, anticipate their behavior within the body, and even create completely new molecules. AI is also applied in drug repurposing and personalizing therapies by discovering new applications for existing medications or customizing treatments for individual patients based on their specific data.
The market for AI in drug discovery is expected to grow significantly due to the increasing need for advanced therapeutic medications aimed at a wide array of medical conditions. With the rising prevalence of chronic illnesses worldwide, pharmaceutical companies are enhancing their investment in research and development to fulfill the persistent demand for new medications.
Strategic Insights for Senior Leaders
Key Drivers Propelling Growth of AI in Drug Discovery Market
The primary factors propelling the AI in drug discovery market include the use of AI in drug discovery are its capability to quickly analyze large datasets, forecast molecular characteristics and toxicity, discover new drug targets, and speed up the process of repurposing existing medications. AI enhances the drug development process by employing machine learning to better predict a drug candidate’s effectiveness, safety, and pharmacokinetic traits, ultimately resulting in lower expenses and shorter timelines. Other significant growth drivers, include the increasing investments and funding from private and public sectors, rising adoption of AI-driven platforms for target identification, lead optimization, toxicity prediction, and safety profiling.
Role of AI in Personalized Medicine
Artificial intelligence significantly contributes to personalized medicine by examining large datasets to facilitate tailored treatments, enhance diagnostics, and speed up the process of drug discovery. It combines information from genomics, electronic health records, and wearable technology to forecast disease risk, refine medication plans, and discover new therapeutic targets. This results in more precise diagnostics, improved patient outcomes, and more effective healthcare systems.
AI in Drug Discovery Market: Competitive Landscape of Companies in this Industry
The competitive landscape of AI in drug discovery market is characterized by intense competition, featuring a combination of large and smaller firms. Key players in this field include NVIDIA, Insilico Medicine, Exscientia, BenevolentAI, Google DeepMind, IBM, and Microsoft, which have created sophisticated AI systems for target identification, generative chemistry, and optimizing clinical trials. Major pharmaceutical organizations, such as AstraZeneca, Pfizer, Roche, Novartis, and Bayer are actively collaborating with AI firms to utilize machine learning for more rapid and economical drug development processes.
Startups such as Atomwise, Recursion Pharmaceuticals, and BenchSci bring innovation with their distinct AI-focused methodologies, while investments and partnerships are rapidly rising to meet the growing demand for precision medicine and new therapeutics. The market, which is projected for substantial growth, shows robust momentum driven by the capability of AI capability to process intricate biological data, shorten R&D timelines, and improve the success rates of drug candidates worldwide.
AI in Drug Discovery Evolution: Emerging Trends in the Industry
Emerging trends in this domain include the utilization of generative AI to create new molecules, the incorporation of multi-omics data for a comprehensive understanding of diseases, and the use of Large Language Models (LLMs) to examine scientific literature. Additional advancements include the employment of State Space Models (SSMs), which provide enhanced computational efficiency, and the integration of AI in personalized medicine, where AI develops customized treatment plans by evaluating individual patient data.
Key Market Challenges
The market for AI in drug discovery faces significant challenges, including data and technical limitations, as well as regulatory and ethical issues, and operational obstacles. The quality and availability of data are pivotal concerns, as pharmaceutical datasets frequently suffer from fragmentation, inconsistencies, incompleteness, or poor annotations. This can result in biased predictions and unreliable outcomes from AI systems.
Further, the intricate nature of biological systems makes comprehensive computational modeling difficult and is further complicated by the high computational expenses that can be burdensome for smaller organizations. Additionally, regulatory uncertainties arise from changing FDA and EMA guidelines that do not align well with the iterative characteristics of AI, ethical dilemmas such as data privacy issues under HIPAA/GDPR, and intellectual property disputes concerning the patenting of drugs developed by AI.
AI in Drug Discovery Market: Key Market Share Insights
Market Share by Drug Discovery Step
Based on the drug discovery step, the global market is segmented into target identification / validation, hit generation / lead identification and lead optimization. According to our estimates, currently, lead optimization captures majority share of the market. The application of AI in the initial phases of drug discovery, particularly in lead optimization, is crucial for improving the drug's efficacy, accessibility, and safety profile. Additionally, lead optimization is vital for enhancing solubility, cellular permeability, and stability.
Market Share by Geography
According to our estimates North America currently captures a significant share of the AI in drug discovery market. This is due to the increasing utilization of AI-based tools by pharmaceutical companies for drug discovery and the rise in partnership agreements aimed at improving product offerings in North America. It is also important to note that the AI in drug discovery market in the Asia-Pacific region is expected to grow at a higher CAGR over the forecast period.
Example Players in AI in Drug Discovery Market
- Aiforia Technologies
- Atomwise
- BioSyntagma
- Chemalive
- Collaborations Pharmaceuticals
- Cyclica
- DeepMatter
- Recursion
- InveniAI
- MAbSilico
- Optibrium
- Recursion Pharmaceuticals
- Sensyne Health
- Valo Health
AI in Drug Discovery Market: Report Coverage
The report on the AI in drug discovery market features insights on various sections, including:
- Market Sizing and Opportunity Analysis: An in-depth analysis of the AI in drug discovery market, focusing on key market segments, including [A] drug discovery steps, [B] therapeutic area, and [C] key geographical regions.
- Competitive Landscape: A comprehensive analysis of the companies engaged in the AI in drug discovery market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters and [D] ownership structure.
- Company Profiles: Elaborate profiles of prominent players engaged in the AI in drug discovery market, providing details on [A] location of headquarters, [B] company size, [C] company mission, [D] company footprint, [E] management team, [F] contact details, [G] financial information, [H] operating business segments, [I] portfolio, [J] recent developments, and an informed future outlook.
- Megatrends: An evaluation of ongoing megatrends in the AI in drug discovery industry.
- Patent Analysis: An insightful analysis of patents filed / granted in the AI in drug discovery domain, based on relevant parameters, including [A] type of patent, [B] patent publication year, [C] patent age and [D] leading players.
- Recent Developments: An overview of the recent developments made in the AI in drug discovery market, along with analysis based on relevant parameters, including [A] year of initiative, [B] type of initiative, [C] geographical distribution and [D] most active players.
- Porter’s Five Forces Analysis: An analysis of five competitive forces prevailing in the AI in drug discovery market, including threats of new entrants, bargaining power of buyers, bargaining power of suppliers, threats of substitute products and rivalry among existing competitors.
- SWOT Analysis: An insightful SWOT framework, highlighting the strengths, weaknesses, opportunities and threats in the domain. Additionally, it provides Harvey ball analysis, highlighting the relative impact of each SWOT parameter.
- Value Chain Analysis: A comprehensive analysis of the value chain, providing information on the different phases and stakeholders involved in the AI in drug discovery market.
Key Questions Answered in this Report
- What is the current and future market size?
- Who are the leading companies in this market?
- What are the growth drivers that are likely to influence the evolution of this market?
- What are the key partnership and funding trends shaping this industry?
- Which region is likely to grow at higher CAGR till 2040?
- How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
- Detailed Market Analysis: The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- In-depth Analysis of Trends: Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. Each report maps ecosystem activity across partnerships, funding, and patent landscapes to reveal growth hotspots and white spaces in the industry.
- Opinion of Industry Experts: The report features extensive interviews and surveys with key opinion leaders and industry experts to validate market trends mentioned in the report.
- Decision-ready Deliverables: The report offers stakeholders with strategic frameworks (Porter’s Five Forces, value chain, SWOT), and complimentary Excel / slide packs with customization support.
Additional Benefits
- Complimentary Dynamic Excel Dashboards for Analytical Modules
- Exclusive 15% Free Content Customization
- Personalized Interactive Report Walkthrough with the Expert Research Team
- Free Updates for Reports that are 6+ Months Old
This product will be delivered within 3-5 business days.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aiforia Technologies
- Atomwise
- BioSyntagma
- Chemalive
- Collaborations Pharmaceuticals
- Cyclica
- DeepMatter
- Recursion
- InveniAI
- MAbSilico
- Optibrium
- Recursion Pharmaceuticals
- Sensyne Health
- Valo Health
Methodology
LOADING...
